Search

Arvinas Inc

Closed

SectorHealthcare

9.32 -0.43

Overview

Share price change

24h

Current

Min

9.03

Max

9.36

Key metrics

By Trading Economics

Income

227M

169M

Sales

234M

250M

P/E

Sector Avg

35.385

57.371

EPS

2.58

Profit margin

67.841

Employees

246

EBITDA

216M

159M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+59.83% upside

Dividends

By Acuity

Next Earnings

4 Nov 2026

Market Stats

By TradingEconomics

Market Cap

74M

594M

Previous open

9.75

Previous close

9.32

News Sentiment

By Acuity

47%

53%

145 / 340 Healthcare

Arvinas Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Aug 2026, 19:56 UTC

Arvinas Inc. shares are lower today amid broader market pressures, including a significant drop in crude oil prices linked to U.S.-Iran relations.

21 Aug 2026, 19:56 UTC

Arvinas Inc is trading higher, reflecting broader market gains despite no specific company news. The stock remains above its 20-day moving average.

20 Aug 2026, 20:01 UTC

Arvinas Inc shares are lower today, reflecting broader market pressures amid concerns over consumer spending following Walmart Inc's disappointing earnings report.

19 Aug 2026, 19:26 UTC

News

Arvinas Inc shares are higher, buoyed by positive analyst ratings. BTIG maintains a "buy" with an $18 target, while Barclays raises its target to $20.

17 Aug 2026, 19:16 UTC

Arvinas Inc shares are higher during Monday's session, reflecting positive market performance. The stock has gained since Friday's close, despite a decline in retail sales.

14 Aug 2026, 19:46 UTC

Arvinas Inc shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

13 Aug 2026, 19:46 UTC

Arvinas Inc. shares are higher today, maintaining a position above their 20-day moving average and near the upper end of their one-month range.

11 Aug 2026, 19:26 UTC

Arvinas Inc. shares are trading lower as the Pharmaceuticals sub-sector declines, despite a peak shortly after the market opened. No specific news was identified.

10 Aug 2026, 19:56 UTC

News

Analysts updated ratings on Arvinas Inc, with Citigroup lowering its target to $21 and Evercore ISI reducing its target to $14. Shares are trading higher.

7 Aug 2026, 19:51 UTC

Arvinas Inc is rising amid a broader market rally, with no specific company news driving the move. The stock remains above its 20-day moving average.

6 Aug 2026, 19:46 UTC

News

Arvinas Inc reported earnings per share of $2.58, exceeding estimates. Revenue reached $249.7 million, driving shares higher in Thursday's session.

5 Aug 2026, 20:03 UTC

News

Arvinas shares are lower following Wells Fargo's downgrade to Equal-Weight and a price target cut to $11, despite Wedbush raising its target to $12.

4 Aug 2026, 20:02 UTC

Social Media
News

Arvinas Inc shares rose following strong Q2 results, with EPS of $2.58 and revenue of $249.7 million, surpassing analyst expectations. BTIG reiterated its Buy rating.

3 Aug 2026, 19:46 UTC

News

Arvinas Inc. shares are lower today, continuing a downward trend since Friday. Barclays raised its price target from $18.00 to $20.00 while maintaining an "overweight" rating.

31 Jul 2026, 20:06 UTC

Arvinas Inc shares are declining amid broader market trends and rising Treasury yields. The stock remains below its 20-day moving average.

29 Jul 2026, 16:36 UTC

Arvinas shares are lower today, trading near the lower end of their one-month range amid rising oil prices and inflation concerns.

28 Jul 2026, 20:06 UTC

Arvinas Inc's shares are lower today, reflecting broader market trends amid a significant decline in Asian indices, particularly the Nikkei 225.

24 Jul 2026, 19:26 UTC

Arvinas Inc. shares are lower amid a broader market decline influenced by falling crude oil prices, now near the lower end of their one-month range.

22 Jul 2026, 20:06 UTC

Arvinas Inc. shares are near unchanged amid routine trading and cautious market sentiment ahead of the Federal Reserve meeting.

21 Jul 2026, 20:06 UTC

Arvinas Inc shares are higher during Tuesday's session, tracking gains in the Nasdaq 100 Index amid strong technology sector performance. No specific news was identified.

Peer Comparison

Price change

Arvinas Inc Forecast

Price Target

By TipRanks

59.83% upside

12 Months Forecast

Average 14.96 USD  59.83%

High 21 USD

Low 8.68 USD

Based on 11 Wall Street analysts offering 12 month price targets forArvinas Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

5

Buy

6

Hold

0

Sell

Sentiment

By Acuity

145 / 340 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
help-icon Live chat